Clinical Trial Update: Futibatinib in Patients With Specific FGFR Aberrations [Phase 2]

View source ↗

Summary

Taiho Oncology reports a Phase 2 trial of futibatinib in patients with FGFR aberrations across advanced cancers. The study (NCT04189445) was terminated, and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Cancer
• Lymphoid Neoplasms
• Myeloid Neoplasms
• Solid Tumors

Drugs mentioned

• Futibatinib (futibatinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-10-08